| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Umit Kazim Ozdogan, Janne Lähdesmäki, Kristo Hakala, Mika Scheini. The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. European journal of pharmacology. vol 497. issue 2. 2005-03-15. PMID:15306201. |
the effects of two alpha(2)-adrenoceptor agonists, clonidine (2 mg/kg) and dexmedetomidine (20 and 100 microg/kg), and the alpha(1)-adrenoceptor antagonist prazosin (0.5 mg/kg) were tested on morphine analgesia, tolerance, and withdrawal in wild-type and alpha(2a)-adrenoceptor knock-out (ko) mice. |
2005-03-15 |
2023-08-12 |
mouse |
| Umit Kazim Ozdogan, Janne Lähdesmäki, Kristo Hakala, Mika Scheini. The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. European journal of pharmacology. vol 497. issue 2. 2005-03-15. PMID:15306201. |
clonidine and dexmedetomidine had no analgesic effects in alpha(2a)-adrenoceptor ko mice, but morphine analgesia and tolerance were similar in both genotypes. |
2005-03-15 |
2023-08-12 |
mouse |
| Kazuko Taij. [Dexmedetomidine hydrochloride (Precedex), a new sedative in intensive care, its pharmacological characteristics and clinical study result]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. vol 124. issue 3. 2005-03-01. PMID:15333990. |
dexmedetomidine hydrochloride (precedex) is a potent and highly selective central alpha(2)-adrenoreceptor agonist. |
2005-03-01 |
2023-08-12 |
mouse |
| Kazuyoshi Hirota, Hiroki Nomura, Mihoko Kudo, Naohiro Mori, Tsuyoshi Kudo, Tetsuya Kushikat. Supraclinical concentrations of dexmedetomidine evoke norepinephrine release from rat cerebrocortical slices possible involvement of the orexin-1 receptor. Neuroscience letters. vol 372. issue 1-2. 2005-01-14. PMID:15531105. |
dexmedetomidine is a highly selective alpha(2)-agonist and reduces norepinephrine release from several neuronal tissues. |
2005-01-14 |
2023-08-12 |
rat |
| Kazuyoshi Hirota, Hiroki Nomura, Mihoko Kudo, Naohiro Mori, Tsuyoshi Kudo, Tetsuya Kushikat. Supraclinical concentrations of dexmedetomidine evoke norepinephrine release from rat cerebrocortical slices possible involvement of the orexin-1 receptor. Neuroscience letters. vol 372. issue 1-2. 2005-01-14. PMID:15531105. |
we have also used a selective alpha(2)-antagonist yohimbine and an orexin-1 receptor antagonist sb-334867 to examine whether the effects of dexmedetomidine on norepinephrine release are mediated via alpha(2)-adrenergic or orexin (ox) receptors. |
2005-01-14 |
2023-08-12 |
rat |
| Kazuyoshi Hirota, Hiroki Nomura, Mihoko Kudo, Naohiro Mori, Tsuyoshi Kudo, Tetsuya Kushikat. Supraclinical concentrations of dexmedetomidine evoke norepinephrine release from rat cerebrocortical slices possible involvement of the orexin-1 receptor. Neuroscience letters. vol 372. issue 1-2. 2005-01-14. PMID:15531105. |
thus, supraclinical concentrations of dexmedetomidine increase norepinephrine release from rat cerebrocortical slices, and this release may be mediated via ox(1) but not alpha(2)-adrenoceptors. |
2005-01-14 |
2023-08-12 |
rat |
| Julia C Finkel, Ahmed Elrefa. The use of dexmedetomidine to facilitate opioid and benzodiazepine detoxification in an infant. Anesthesia and analgesia. vol 98. issue 6. 2004-07-14. PMID:15155322. |
we used dexmedetomidine, an alpha(2)-adrenergic agonist, to facilitate opioid and benzodiazepine withdrawal. |
2004-07-14 |
2023-08-12 |
Not clear |
| Cecilia Dawson, Daqing Ma, Andre Chow, Mervyn Maz. Dexmedetomidine enhances analgesic action of nitrous oxide: mechanisms of action. Anesthesiology. vol 100. issue 4. 2004-05-25. PMID:15087625. |
nitrous oxide and dexmedetomidine are thought to mediate analgesia (antinociception in a noncommunicative organism) via alpha 2b- and alpha 2a-adrenergic receptor subtypes within the spinal cord, respectively. |
2004-05-25 |
2023-08-12 |
Not clear |
| M Frances Davies, Janet Tsui, Judy A Flannery, Xiangqi Li, Timothy M DeLorey, Brian B Hoffma. Activation of alpha2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 2. 2004-04-27. PMID:14583739. |
alpha(2) adrenergic agonists such as dexmedetomidine generally suppress noradrenergic transmission and have sedative, analgesic, and antihypertensive properties. |
2004-04-27 |
2023-08-12 |
mouse |
| M Frances Davies, Janet Tsui, Judy A Flannery, Xiangqi Li, Timothy M DeLorey, Brian B Hoffma. Activation of alpha2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 2. 2004-04-27. PMID:14583739. |
dexmedetomidine's action on discrete cue memory did not occur in alpha(2a) adrenoceptor knockout (ko) mice. |
2004-04-27 |
2023-08-12 |
mouse |
| M Frances Davies, Janet Tsui, Judy A Flannery, Xiangqi Li, Timothy M DeLorey, Brian B Hoffma. Activation of alpha2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 2. 2004-04-27. PMID:14583739. |
when dexmedetomidine was administered after training, it suppressed contextual memory, an effect that did not occur in alpha(2a) adrenoceptor ko mice. |
2004-04-27 |
2023-08-12 |
mouse |
| M Frances Davies, Janet Tsui, Judy A Flannery, Xiangqi Li, Timothy M DeLorey, Brian B Hoffma. Activation of alpha2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 29. issue 2. 2004-04-27. PMID:14583739. |
we conclude that dexmedetomidine, acting at alpha(2a) adrenoceptors, must be present during the encoding process to decrease discrete cue fear memory; however, its ability to suppress contextual memory is likely the result of blocking the consolidation process. |
2004-04-27 |
2023-08-12 |
mouse |
| Antti Haapalinna, Tiina Leino, Esa Heinone. The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn-Schmiedeberg's archives of pharmacology. vol 368. issue 5. 2004-02-10. PMID:14566451. |
dexmedetomidine, an alpha(2)-adrenoceptor agonist and the alpha(2)-adrenoceptor antagonists idazoxan and yohimbine were used as reference compounds. |
2004-02-10 |
2023-08-12 |
rat |
| Tariq A Khasawinah, Alejandro Ramirez, John W Berkenbosch, Joseph D Tobia. Preliminary experience with dexmedetomidine in the treatment of cyclic vomiting syndrome. American journal of therapeutics. vol 10. issue 4. 2003-11-05. PMID:12845396. |
dexmedetomidine is an alpha(2) adrenergic agonist with an increased specificity for the alpha(2) versus the alpha(1) receptor when compared with clonidine. |
2003-11-05 |
2023-08-12 |
Not clear |
| J Mant. Dexmedetomidine. Drugs of today (Barcelona, Spain : 1998). vol 35. issue 3. 2003-10-24. PMID:12973380. |
dexmedetomidine is a potent, highly selective alpha(2)-adrenoceptor agonist. |
2003-10-24 |
2023-08-12 |
Not clear |
| Catarina A Owesson, Isabelle Seif, Daniel P McLaughlin, Jonathan A Stamfor. Different alpha(2) adrenoceptor subtypes control noradrenaline release and cell firing in the locus coeruleus of wildtype and monoamine oxidase-A knockout mice. The European journal of neuroscience. vol 18. issue 1. 2003-09-29. PMID:12859335. |
on short stimulus trains (10 pulses, 200 hz), the alpha(2) agonist dexmedetomidine (10 nm) reduced na efflux by 78 +/- 8% and 51 +/- 8% in wildtype and mao-a ko mice, respectively. |
2003-09-29 |
2023-08-12 |
mouse |
| Liang Peng, Albert C H Yu, King Y Fung, Vincent Prévot, Leif Hert. Alpha-adrenergic stimulation of ERK phosphorylation in astrocytes is alpha(2)-specific and may be mediated by transactivation. Brain research. vol 978. issue 1-2. 2003-09-08. PMID:12834899. |
the highly specific alpha(2)-adrenergic agonist, dexmedetomidine, has hypnotic-sedative, anesthetic-sparing and analgesic effects, and it protects neurons against ischemia. |
2003-09-08 |
2023-08-12 |
mouse |
| Liang Peng, Albert C H Yu, King Y Fung, Vincent Prévot, Leif Hert. Alpha-adrenergic stimulation of ERK phosphorylation in astrocytes is alpha(2)-specific and may be mediated by transactivation. Brain research. vol 978. issue 1-2. 2003-09-08. PMID:12834899. |
the alpha(1)-adrenergic agonist, phenylephrine, does not share dexmedetomidine's pharmacological properties, although both dexmedetomidine and phenylephrine increase free cytosolic ca(2+) ([ca(2+)](i)) in astrocytes, and most of dexmedetomidine's actions in the brain are exerted on postjunctional receptors. |
2003-09-08 |
2023-08-12 |
mouse |
| Liang Peng, Albert C H Yu, King Y Fung, Vincent Prévot, Leif Hert. Alpha-adrenergic stimulation of ERK phosphorylation in astrocytes is alpha(2)-specific and may be mediated by transactivation. Brain research. vol 978. issue 1-2. 2003-09-08. PMID:12834899. |
the cultures were incubated with dexmedetomidine concentrations known to be pharmacologically active and to act specifically on alpha(2)-adrenergic receptors (25-100 nm). |
2003-09-08 |
2023-08-12 |
mouse |
| Janne Lähdesmäki, Jukka Sallinen, Ewen MacDonald, Jouni Sirviö, Mika Scheini. Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype. Neuropharmacology. vol 44. issue 7. 2003-08-04. PMID:12726820. |
metabolism of brain monoamine neurotransmitters, locomotor activity and body temperature were investigated in mice with targeted inactivation of the gene encoding alpha(2a)-ar (alpha(2a)-knockout, alpha(2a)-ko) and wild-type (wt) mice after treatment with the alpha(2)-ar agonist dexmedetomidine and the antagonist atipamezole. |
2003-08-04 |
2023-08-12 |
mouse |